SNAP-8
Cosmetic peptide
An eight-amino-acid peptide used in cosmetic formulations. Published evidence is mostly laboratory work and manufacturer testing.
Pal-GHK
Also cited in the literature as Palmitoyl tripeptide-1
A fat-modified version of the GHK tripeptide used in skincare. Human data comes mainly from tests of complete formulations.
Regulatory status: Not licensed as a medicine in the United Kingdom. It holds no MHRA marketing authorisation, has no approved indication, and is not approved for human or animal use.
Cell & tissue research
Research stage: Cosmetic formulation studies only
Cells
Animal studies
Human trials
The research pathway — not every compound has reached human trials. Illustrations are simplified, not study results.
What it is
Pal-GHK is the tripeptide glycine-histidine-lysine with a palmitic acid chain attached, a change intended to help it pass through the outer layer of skin.
How researchers think it works
Laboratory studies of the parent tripeptide reported signalling that increased collagen production in skin cell cultures.
What has research seen in people?
Human data comes from tests of complete skincare formulations, which reported measured changes in skin roughness and wrinkle depth.
Because those products contained several active ingredients, results could not be attributed to this peptide alone.
Laboratory work on the parent tripeptide reported increased collagen production in skin cells.
Where this material is listed
For laboratory research use only. Not a medicine and not for human or animal use.
Veritide does not sell or supply anything. This links to a third-party UK laboratory supplier; we may earn a commission if you buy through it, at no extra cost to you. Materials are sold for laboratory research use only and are not licensed medicines.
What studies have found
- Published human data mostly tested finished cosmetic products containing this peptide alongside others, reporting measured changes in skin roughness and wrinkle depth.
- Because the products combined several ingredients, researchers could not attribute results to this peptide alone.
What we still do not know
- Studies were small, often supplier-funded, and tested mixtures rather than the single ingredient.
- No medicinal claims are supported by the published record.
Sources
Related profiles
Retatrutide
Triple incretin receptor agonist
An experimental peptide that acts on three hormone receptors. Researchers studied it in phase 2 trials involving weight and blood sugar.
Mazdutide
Dual GLP-1 / glucagon receptor agonist
An experimental peptide based on a natural gut hormone. Researchers studied it mainly in phase 2 and phase 3 trials in China.